Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining.
Hepatocellular carcinoma (HCC)
immune, prognosis
tumor mutation burden (TMB)
Journal
Journal of gastrointestinal oncology
ISSN: 2078-6891
Titre abrégé: J Gastrointest Oncol
Pays: China
ID NLM: 101557751
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
20
04
2021
accepted:
26
05
2021
entrez:
23
7
2021
pubmed:
24
7
2021
medline:
24
7
2021
Statut:
ppublish
Résumé
The aim of this study was to determine the relationship between tumor mutation burden (TMB) and prognosis of patients with hepatocellular carcinoma (HCC), and to explore the differential expression of genes in HCC by TMB and the relationship between immune cells, TMB, and HCC. Somatic variation data, gene transcriptional expression data and clinical information of patients with HCC were obtained from cancer genome map (TCGA) database. Analyze the characteristics of the gene mutation data of the sample, divide the high and low TMB groups and draw the survival curve at the same time, carry on the difference analysis to the gene of TMB, further carry on the univariate Cox regression analysis and Lasso regression analysis and construct the clinical model. Download the dataset GSE14520, from the Gene Expression Omnibus (GEO) database to verify the genes of the prognostic model. The differential genes were analyzed by gene ontology (GO) enrichment analysis and Kyoto encyclopedia of genes and genomes by (KEGG) enrichment analysis. Then the relative abundance of 22 immune cell types in HCC and normal control samples was calculated. Finally, the correlation between the scores of immune cells and Risk model was analyzed. Tumor protein p53 ( There is a negative correlation between TMB and the prognosis of patients with HCC. TMB has an effect on the differential expression of genes in HCC cells and the distribution of immune cells in tumor tissues.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to determine the relationship between tumor mutation burden (TMB) and prognosis of patients with hepatocellular carcinoma (HCC), and to explore the differential expression of genes in HCC by TMB and the relationship between immune cells, TMB, and HCC.
METHODS
METHODS
Somatic variation data, gene transcriptional expression data and clinical information of patients with HCC were obtained from cancer genome map (TCGA) database. Analyze the characteristics of the gene mutation data of the sample, divide the high and low TMB groups and draw the survival curve at the same time, carry on the difference analysis to the gene of TMB, further carry on the univariate Cox regression analysis and Lasso regression analysis and construct the clinical model. Download the dataset GSE14520, from the Gene Expression Omnibus (GEO) database to verify the genes of the prognostic model. The differential genes were analyzed by gene ontology (GO) enrichment analysis and Kyoto encyclopedia of genes and genomes by (KEGG) enrichment analysis. Then the relative abundance of 22 immune cell types in HCC and normal control samples was calculated. Finally, the correlation between the scores of immune cells and Risk model was analyzed.
RESULTS
RESULTS
Tumor protein p53 (
CONCLUSIONS
CONCLUSIONS
There is a negative correlation between TMB and the prognosis of patients with HCC. TMB has an effect on the differential expression of genes in HCC cells and the distribution of immune cells in tumor tissues.
Identifiants
pubmed: 34295561
doi: 10.21037/jgo-21-259
pii: jgo-12-03-1117
pmc: PMC8261312
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1117-1131Informations de copyright
2021 Journal of Gastrointestinal Oncology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jgo-21-259). The authors have no conflicts of interest to declare.
Références
Exp Mol Med. 2016 Dec 2;48(12):e275
pubmed: 27909336
J Clin Oncol. 2019 Apr 20;37(12):992-1000
pubmed: 30785829
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Rev Mol Cell Biol. 2014 Dec;15(12):786-801
pubmed: 25415508
Gastroenterology. 2018 Dec;155(6):1936-1950.e17
pubmed: 30145359
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Cell Biosci. 2019 Sep 26;9:79
pubmed: 31572568
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
Cell Death Dis. 2018 Mar 22;9(4):432
pubmed: 29568064
Oncologist. 2020 Jan;25(1):e147-e159
pubmed: 31578273
EBioMedicine. 2017 Aug;22:58-67
pubmed: 28754304
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):681-700
pubmed: 26484443
J Mol Endocrinol. 2009 Nov;43(5):179-85
pubmed: 19433493
J Biol Chem. 2012 Jun 1;287(23):19516-27
pubmed: 22511756
Lancet Oncol. 2016 Jul;17(7):883-895
pubmed: 27269741
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Hepatology. 2014 Apr;59(4):1415-26
pubmed: 24002931
Tumour Biol. 2015 Aug;36(8):6211-21
pubmed: 25753478
Cancer Med. 2019 Sep;8(12):5702-5715
pubmed: 31385458
Cancer Res. 2018 May 1;78(9):2305-2317
pubmed: 29440144
Cancers (Basel). 2018 Aug 07;10(8):
pubmed: 30087253
Nat Commun. 2016 Jan 27;7:10321
pubmed: 26813785
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
Oncotarget. 2017 Dec 21;9(15):12487-12502
pubmed: 29552328
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Cancers (Basel). 2019 Dec 03;11(12):
pubmed: 31816940
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Pharmacol Ther. 2015 Mar;147:22-31
pubmed: 25444759
Mol Biol Cell. 2011 Nov;22(22):4302-11
pubmed: 21937724
Cancer Lett. 2020 Mar 31;473:25-32
pubmed: 31875523
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Cancer Cell. 2018 May 14;33(5):843-852.e4
pubmed: 29657128
Cancer Lett. 2014 Oct 1;352(2):160-8
pubmed: 24892648
Oncogene. 2017 Feb 16;36(7):979-988
pubmed: 27524416
World J Surg Oncol. 2018 Jan 16;16(1):9
pubmed: 29338742
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
J Exp Clin Cancer Res. 2018 Aug 29;37(1):203
pubmed: 30157906
J Hepatol. 2018 Mar;68(3):526-549
pubmed: 28989095
Gastroenterology. 2014 Dec;147(6):1393-404
pubmed: 25181692
Mediators Inflamm. 2016;2016:6058147
pubmed: 26966341
Gut. 2020 Oct;69(10):1904-1906
pubmed: 31852768
Br J Cancer. 2018 Jan;118(2):233-247
pubmed: 29123267
FEBS Lett. 2016 Aug;590(15):2375-97
pubmed: 27404485
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
J Immunother Cancer. 2019 Nov 29;7(1):331
pubmed: 31783783